274 related articles for article (PubMed ID: 30529073)
1. Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma.
Zhao L; Okhovat JP; Hong EK; Kim YH; Wood GS
Neoplasia; 2019 Jan; 21(1):82-92. PubMed ID: 30529073
[TBL] [Abstract][Full Text] [Related]
2. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
[TBL] [Abstract][Full Text] [Related]
3. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
Cyrenne BM; Lewis JM; Weed JG; Carlson KR; Mirza FN; Foss FM; Girardi M
Blood; 2017 Nov; 130(19):2073-2083. PubMed ID: 28972015
[TBL] [Abstract][Full Text] [Related]
4. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.
Tiffon C; Adams J; van der Fits L; Wen S; Townsend P; Ganesan A; Hodges E; Vermeer M; Packham G
Br J Pharmacol; 2011 Apr; 162(7):1590-602. PubMed ID: 21198545
[TBL] [Abstract][Full Text] [Related]
5. SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis.
Nihal M; Ahmad N; Wood GS
Cell Cycle; 2014; 13(4):632-40. PubMed ID: 24343700
[TBL] [Abstract][Full Text] [Related]
6. Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma.
Andrews JM; Schmidt JA; Carson KR; Musiek AC; Mehta-Shah N; Payton JE
EBioMedicine; 2019 Aug; 46():170-183. PubMed ID: 31358475
[TBL] [Abstract][Full Text] [Related]
7. Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines.
Hölscher AS; Schulz WA; Pinkerneil M; Niegisch G; Hoffmann MJ
Clin Epigenetics; 2018; 10():1. PubMed ID: 29312470
[TBL] [Abstract][Full Text] [Related]
8. Functional Depletion of HSP72 by siRNA and Quercetin Enhances Vorinostat-Induced Apoptosis in an HSP72-Overexpressing Cutaneous T-Cell Lymphoma Cell Line, Hut78.
Fujii K; Idogawa M; Suzuki N; Iwatsuki K; Kanekura T
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681913
[TBL] [Abstract][Full Text] [Related]
9. Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism.
Chen J; Fiskus W; Eaton K; Fernandez P; Wang Y; Rao R; Lee P; Joshi R; Yang Y; Kolhe R; Balusu R; Chappa P; Natarajan K; Jillella A; Atadja P; Bhalla KN
Blood; 2009 Apr; 113(17):4038-48. PubMed ID: 19074726
[TBL] [Abstract][Full Text] [Related]
10. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the Effect of Gentian Violet on Apoptosis and Proliferation in Cutaneous T-Cell Lymphoma in an In Vitro Study.
Wu J; Wood GS
JAMA Dermatol; 2018 Oct; 154(10):1191-1198. PubMed ID: 30167641
[TBL] [Abstract][Full Text] [Related]
12. Combined inhibition of Bcl-2 and NFκB synergistically induces cell death in cutaneous T-cell lymphoma.
Froehlich TC; Müller-Decker K; Braun JD; Albrecht T; Schroeder A; Gülow K; Goerdt S; Krammer PH; Nicolay JP
Blood; 2019 Aug; 134(5):445-455. PubMed ID: 31167801
[TBL] [Abstract][Full Text] [Related]
13. NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.
Kießling MK; Nicolay JP; Schlör T; Klemke CD; Süss D; Krammer PH; Gülow K
Oncotarget; 2017 Jul; 8(28):45687-45697. PubMed ID: 28537899
[TBL] [Abstract][Full Text] [Related]
14. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma.
Bhadury J; Nilsson LM; Muralidharan SV; Green LC; Li Z; Gesner EM; Hansen HC; Keller UB; McLure KG; Nilsson JA
Proc Natl Acad Sci U S A; 2014 Jul; 111(26):E2721-30. PubMed ID: 24979794
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas.
Kitadate A; Ikeda S; Teshima K; Ito M; Toyota I; Hasunuma N; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
Oncogene; 2016 Jul; 35(28):3692-704. PubMed ID: 26640145
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma.
Umamaheswari A; Puratchikody A; Hari N
Anticancer Agents Med Chem; 2019; 19(7):916-934. PubMed ID: 30836926
[TBL] [Abstract][Full Text] [Related]
17. BCL11B-Mediated Epigenetic Repression Is a Crucial Target for Histone Deacetylase Inhibitors in Cutaneous T-Cell Lymphoma.
Fu W; Yi S; Qiu L; Sun J; Tu P; Wang Y
J Invest Dermatol; 2017 Jul; 137(7):1523-1532. PubMed ID: 28288848
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist.
Frew AJ; Lindemann RK; Martin BP; Clarke CJ; Sharkey J; Anthony DA; Banks KM; Haynes NM; Gangatirkar P; Stanley K; Bolden JE; Takeda K; Yagita H; Secrist JP; Smyth MJ; Johnstone RW
Proc Natl Acad Sci U S A; 2008 Aug; 105(32):11317-22. PubMed ID: 18685088
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
[TBL] [Abstract][Full Text] [Related]
20. Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells.
Cortiguera MG; García-Gaipo L; Wagner SD; León J; Batlle-López A; Delgado MD
Sci Rep; 2019 Nov; 9(1):16495. PubMed ID: 31712669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
